Dear Reader,
A cancer drug that can extend lives is also pushing patients and public health systems to the brink.
By now, you may have had a chance to read our latest investigation, Cancer Calculus, which examines how Merck’s blockbuster cancer drug Keytruda generates enormous revenues—while pricing out patients and straining public health systems.
Within days of publication, lawmakers and activists in the United States, Europe, and Mexico reacted publicly. The findings struck a nerve that could not be ignored. In countries including the Netherlands, Belgium and Finland, officials have already called for inquiries into the pricing and transparency practices surrounding Keytruda. And this is just the beginning.
Moments like this—when reporting leads directly to scrutiny and the possibility of change—don’t happen by accident. They require time, collaboration across borders and the independence to follow the facts wherever they lead.
That’s what your support makes possible. If you can, please consider making a gift today to help ICIJ continue uncovering stories that drive accountability worldwide. |
